Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine. Hwang LA, Phang BH, Liew OW, Iqbal J, Koh XH, Koh XY, Othman R, Xue Y, Richards AM, Lane DP, Sabapathy K. Cell Rep. 2018 Jan 2;22(1):299-312.

 Exploiting the p53 Pathway for Therapy. Cheok CF, Lane DP. Cold Spring Harb Perspect Med. 2017 Mar 1;7(3). Review

Going native: Complete removal of protein purification affinity tags by simple modification of existing tags and proteases. Goh HC, Sobota RM, Ghadessy FJ, Nirantar S.Protein Expr Purif. 2017 Jan;129:18-24.

 Anatomy of Mdm2 and Mdm4 in evolution. Tan BX, Liew HP, Chua JS, Ghadessy FJ, Tan YS, Lane DP, Coffill CR. J Mol Cell Biol. 2017 Jan 10. [Epub ahead of print] Review 

The hot-spot p53R172H mutant promotes formation of giant spermatogonia triggered by DNA damage. Xue Y, Raharja A, Sim W, Wong ES, Rahmat SA, Lane DP. Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.374. [Epub ahead of print]

Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides. Wei SJ, Chee S, Yurlova L, Lane D, Verma C, Brown C, Ghadessy F. (2016)  Oncotarget. 2016 Apr 4. doi: 10.18632/oncotarget.8572. [Epub ahead of print]

Stapled peptide design: principles and roles of computation. Tan YS, Lane DP, Verma CS. (2016) Drug Discov Today. 2016 Jun 18. pii: S1359-6446(16)30230-6.

The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans. Coffill CR, Lee AP, Siau JW, Chee SM, Joseph TL, Tan YS, Madhumalar A, Tay BH, Brenner S, Verma CS, Ghadessy FJ, Venkatesh B, Lane DP. (2016) Genes Dev. 2016 Feb 1;30(3):281-92.

A highly sensitive fluorescent light-up probe for real-time detection of the endogenous protein target and its antagonism in live cells. Geng J, Goh WL, Zhang C, Lane DP, Liu B, Ghadessy G, Tan YN. (2015)  Journals of Materials Chemistry B, 2015, 3, 5933-5937.

Long range recognition and selection in IDPs: the interactions of the C-terminus of p53. Kannan S, Lane DP, Verma CS. (2016)  Sci Rep. 2016; 6: 23750.

Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: insights from mdm2 and mdm4 mutant zebrafish. Chua JS, Liew HP, Guo L, Lane DP. (2015) Oncogene. 2015 Mar 9. doi: 10.1038/onc.2015.57. [Epub ahead of print]

A unique role for p53 in the regulation of M2 marcophage polarisation. L Li, DSW Ng, W-C Mah, FF Almeida, SA Rahmat, VK Rao, SC Leow, F Laudisi, MT Peh, AM Goh, JSY Lim, GD Wright, A Mortellaro, R Taneja, F Ginhoux, CG Lee, PK Moore, DP Lane. (2014) Cell Death Differ. 2014 Dec 19. doi: 10.1038/cdd.2014.212. [Epub ahead of print]

 Drugging the p53 pathway: understanding the route to clinical efficacy. Kian Hoe Khoo, Chandra S. Verma & David P. Lane (2014) Nat Rev Drug Discov. 2014 Feb 28;13(3):217-36.

High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia. Tan, B.X., Khoo, K.H., Lim, T.M., Lane, D.P. (2013) Oncotarget. 2013 Nov 22. 

p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. Mondal, A.M., Horikawa, I., Pine, S.R., Fujita, K., Morgan, K.M., Vera, E., Mazur, S.J., Appella, E., Vojtesek, B., Blasco, M.A., Lane, D.P., Harris, C.C. (2013) J Clin Invest. 2013 Dec 2;123(12):5247-57.

Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth. Wong, J.S., Warbrick, E., Vojtesk, B., Hill, J., Lane, D.P. (2013)  Oncotarget. 2013 Jul;4(7):1019-36.

Def defines a conserved nucleolar pathway that leads p53 to proteasome-independent degradation. Tao, T., Shi, H., Guan, Y., Huang, D., Chen, Y., Lane, D.P., Chen, J., Peng, J. (2013) Cell Res. 2013 Jan 29.

Ionising radiation induces a dramatic persistence of p53 protein accumulation and DNA damage signaling in mutant p53 zebrafish. Guo L, Liew HP, Camus S, Goh AM, Chee LL, Lunny DP, Lane EB, Lane DP. (2012)  Oncogene. 2012 Oct 15.

Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. Coffill, C.R., Muller, P.A., Oh, H.K., Neo, S.P., Hogue, K.A., Cheok, C.F., Vousden, K.H., Lane, D.P., Blackstock, W.P., Gunaratne, J. (2012)  EMBO Rep. 2012 Jun 29: 13(7):638-44.  

Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion.Muller, P.A., Trinidad, A.G., Timpson, P., Morton, J.P., Zanivan, S., van den Berghe, P.V., Nixon, C., Karim, S.A., Caswell, P.T., Noll, J.E., Coffill, C.R., Lane, D.P., Sansom, O.J., Neilsen, P.M., Norman, J.C., Vousden, K.H. (2012) Oncogene. 2013 Mar 7;32(10):1252-65.

Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity. Goh, A.M., Lim, C.Y., Chiam, P.C., Li, L., Mann, M.B., Mann, K.M., Menendez, S. and Lane, D.P. (2012) Proc Natl Acad Sci U S A. 109(5), 1685-90.  

Conservation of all three p53 family members and Mdm2 and Mdm4 in the cartilaginous fish. Lane, D.P., Madhumalar, A., Lee, A.P., Tay, B.H., Verma, C., Brenner, S, and Venkatesh B. (2011)  Cell Cycle. 10(24), 4272-9.  

Chemical states of the N-terminal "lid" of MDM2 regulate p53 binding: simulations reveal complexities of modulation. Dastidar, S.G., Raghunathan, D., Nicholson, J., Hupp, T.R., Lane, D.P. and Verma, C.S. (2011) Cell Cycle. 10(1), 82-9.  

A novel unstructured scaffold based on 4EBP1 enables the functional display of a wide range of bioactive peptides. See, H.Y. and Lane, D.P. (2010)  J Mol Biol. 404(5), 819-31.  

Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cheok, C.F., Kua, N., Kaldis, P. and Lane, D.P. (2010) Cell Death Differ. 17(9), 1486-500

Mdm2 and p53 are highly conserved from placozoans to man. Lane, D.P., Cheok, C.F., Brown, C., Madhumalar, A., Ghadessy, F.J. and Verma, C. (2010) Cell Cycle. 9(3), 540-547.

Differential scanning fluorimetry as secondary screening platform for small molecule inhibitors of Bcl-XL.  Wan, K.F., Wang, S., Brown, C.J., Yu, V.C., Entzeroth, M., Lane, D.P. and Lee, M.A. (2009) Cell Cycle. 8(23), 3943-52.

Rational Design and Biophysical Characterization of Thioredoxin-Based Aptamers: Insights into Peptide Grafting. Brown, C.J., Dastidar, S.G., See, H.Y., Coomber, D.W., Ortiz-Lombardía, M., Verma, C. and Lane, D.P. (2009)  J Mol Biol. 395(4), 871-83.

Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around the cap-binding site. Brown, C.J., Verma, C.S., Walkinshaw, M.D. and Lane, D.P. (2009) Cell Cycle. 8, 1905-1911.

p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Chen, J., Ng, S.M., Chang, C., Zhang, Z., Bourdon, J.C., Lane, D.P. and Peng, J. Genes Dev. 2009. 23: 278-90

Discovery, in vivo activity and mechanism of action of a small-molecule p53 activator. Lain, S., Hollick, J.J., Campbell, J., Staples, O.D., Higgins, M., Aoubala, M., McCarthy, A., Appleyard, V., Murray, K.E., Baker, L., Thompson, A., Mathers, J., Holland, S.J., Stark, M.J.R., Pass, G., Woods, J., Lane, D.P. and Westwood, N.J. Cancer Cell. 2008. 13:454-63.

Detection of the p53 response in zebrafish embryos using new monoclonal antibodies.Lee, K.C., Goh, W.L., Xu, M., Kua, N., Lunny, D., Wong, J.S., Coomber, D., Vojtesek, B., Lane, E.B. and Lane, D.P. Oncogene. 2008. 27 (5): 629-40

R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Dey, A., Wong, E.T., Cheok, C.F., Tergaonkar, V. and Lane, D.P. Cell Death Differ. 2008. 15: 263-73.

Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Cheok CF, Dey A, Lane DP. Mol Cancer Res. 2007. 5(11):1133-45.

The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. Stevenson, L.F., Sparks, A., Allende-Vega, N., Xirodimas, D.P., Lane, D.P. and Saville, M.K. EMBO J. 2007. 26:976-86.

Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish.Chen, J., Ruan, H., Ng, S.M., Gao, C., Soo, H.M., Wu, W., Zhang, Z., Wen, Z., Lane, D.P. and Peng, J. Genes Dev. 2005. 19:2900-11.

p53 isoforms can regulate p53 transcriptional activity. Bourdon, J.C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D.P., Saville, M.K. and Lane, D.P. Genes Dev. 2005. 19:2122-37.

From the Cover: Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. Kontopidis, G., Wu, S.Y., Zheleva, D.I., Taylor, P., McInnes, C, Lane, D.P., Fischer, P.M. and Walkinshaw, M.D. Proc Natl Acad Sci U S A. 2005. 102(6):1871-6.

Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Xirodimas, D.P., Saville, M.K., Bourdon, J.C., Hay, R.T. and Lane, D.P. Cell. 2004. 9:83-97.

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Bottger, A., Bottger, V., Sparks, A., Liu,, W.L., Howard, S. and Lane, D.P. Curr Biol. 1997. 7:860-869.

Small peptides activate the latent sequence specific DNA binding function of p53. Hupp, T.R., Sparks, A. and Lane, D.P. Cell. 1995. 83:237-245.

Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes?Lu, X. and Lane, D.P. Cell. 1993. 75:765-778. 

High levels of p53 protein in UV irradiated normal human skin. Hall, P.A., McKee, P.H., Menage, H du P., Dover, R. and Lane, D.P. Oncogene. 1993. 8:203-207.

Cancer - p53, Guardian of the Genome.Lane, D.P. Nature. 1992. 358:15-16.

Regulation of the DNA binding function of p53. Hupp, T.R., Meek, D.W., Midgley, C.A. and Lane, D.P. Cell. 1992. 71:875-886.

Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Bartek, J. Bartkova, J. Vojtesek, B. Staskova, Z. Lukas, J. Rejthar, A. Kovarik, J. Midgley, C.A. Gannon, J.V. and Lane, D.P. Oncogene. 1991. 6:1699-1703.

Increased expression of mutant forms of the p53 oncogene in primary lung cancer. Iggo, R. Gatter K.G. Bartek, J., Lane, D. and Harris, A.L. Lancet. 1990. 335:675-679.

Monoclonal antibody analysis of p53 expression in normal and transformed cells. Yewdell, J.W., Gannon, J.V. and Lane, D.P. J.Virol. 1986. 59:444-452.

SV40 T antigen is bound to a host protein in V40 transformed cells. Lane, D.P. and Crawford, L.V. Nature. 1979. 278:261-263.

Please click here for a full list of David Lane's publications.